HER2 Positive Breast Cancers Completed Phase 3 Trials for Pertuzumab (DB06366)

Also known as: HER2 Positive Breast Cancer

IndicationStatusPhase
DBCOND0066412 (HER2 Positive Breast Cancers)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02125344A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)Treatment